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ABSTRACT
Background: Sarcoidosis is a multiorgan granulomatous
inflammatory disease of unknown aetiology. Familial
clustering of cases and ethnic variation in the epidemiol-
ogy suggests a genetic influence on susceptibility to the
disease. This paper reports twin concordance and
heritability estimates of sarcoidosis in order to assess the
overall contribution of genetic factors to the disease
susceptibility.
Methods: Monozygotic and dizygotic twins enrolled in
the Danish and the Finnish population-based national twin
cohorts (61 662 pairs in total) were linked to diagnostic
information on sarcoidosis obtained from the Danish
National Patient Registry or the Social Insurance
Institution, Finland registry of reimbursed medication using
the 8th and 10th editions of the International Classification
of Diseases. The Fisher exact test was used to compare
probandwise concordance rates in different zygosity
groups. Heritability was estimated based on a multi-
factorial threshold liability model.
Results: A total of 210 twin pairs with at least one
proband with a diagnosis of sarcoidosis were identified.
The probandwise concordance rate was higher in
monozygotic than in dizygotic twins (0.148 vs 0.012).
Compared with the general population there was an 80-
fold increased risk of developing sarcoidosis in co-twins of
affected monozygotic brothers or sisters. The increased
risk in dizygotic twins was only 7-fold. Aetiological model
fitting gave a heritability of sarcoidosis of 0.66 (95% CI
0.45 to 0.80).
Conclusions: This study suggests that genetic factors
play an important role in the susceptibility to sarcoidosis.
This result should encourage the search for molecular
genetic markers of susceptibility to the disease.
Sarcoidosis is a rare multiorgan immune-mediated
disease of unknown aetiology characterised by the
formation of non-caseating granulomas. Ninety
percent of patients are affected in the lungs or
intrathoracic lymph nodes, but large differences in
organ involvement are found between ethnic
groups and in different parts of the world.1–4
The prognosis and course of the disease depends
on the severity and phenotypic characteristics.
Overall, 30% undergo spontaneous remission while
another 30% progress with chronic manifestations.
In addition, a significant number of asymptomatic
cases with sarcoidosis have been identified in mass
screenings using chest radiographs.2 3 5 Mortality
rates in patients with sarcoidosis have been
reported to be 1–6%.2 3 5
The occurrence of sarcoidosis in the general
population remains difficult to establish due to the
wide spectrum of phenotypes, differing diagnostic
criteria and the variable study designs.1 2 6
Incidence rates in Denmark and Finland are 7.2
and 11.4 per 100 000 person-years, respectively.6 7
Prevalence and incidence are dependent on age, sex
and ethnicity.1 2 8–10
The present understanding of the pathogenesis
of the disease is that sarcoidosis is triggered by an
abnormal immune response to an environmental
agent in a genetically predisposed individual.1
Genetic factors are considered to contribute to
the development of sarcoidosis for two main
reasons1 2 6 10; (1) epidemiological studies have
identified ethnicity as an important risk factor;
and (2) familial clustering of cases has been
observed frequently over the last decades. A
previous study has suggested an up to 5.7-fold
increased risk of developing sarcoidosis in siblings
of affected individuals.9 However, the fact that
families do not only share genes but also environ-
ment makes it difficult to determine the relative
contribution of genetic versus environmental
factors to the susceptibility to the disease.
Susceptibility loci have been mapped to the human
leucocyte antigen (HLA) gene complex located on the
short arm of chromosome 6, whereas a number of
non-HLA candidate genes map to other locations in
the genome.10–12 This suggests the influence of a large
number of interacting genes. The specific gene
findings, however, account for only a small fraction
of the variance in risk to the disease.
This study is the first to use the classical twin
method to systematically describe the occurrence
of sarcoidosis in Danish and Finnish twins in order
to address the overall contribution of genetic
factors to the susceptibility to the disease.
METHODS
The twin method is a classic approach to study the
heredity of a disease. Besides sharing their upbring-
ing and early environment, monozygotic twins have
all their genes in common whereas dizygotic twins
only share genes like normal siblings. Therefore, if a
disease is more correlated in monozygotic than in
dizygotic twins, it provides evidence that genetic
factors contribute to the aetiology of the disease.13
Danish and Finnish twin cohorts
The Scandinavian countries have some of the
oldest and most well characterised twin registries
in the world, making collaboration between
countries advantageous when studying rare dis-
eases such as sarcoidosis.14 15 The Danish study
population included all twins enrolled in the
nationwide Danish Twin Registry who were alive
at some point between 1977 and 2004.16 This
comprises a total number of 60 756 pairs. The Old
Finnish Twin Cohort consists of 13 888 pairs of
known zygosity comprising all same-sex twins
born before 1958 with both twins alive in 1975. In
both registries zygosity has been determined using
questions of similarity and mistaken identity.17 This
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method is widely accepted and assigns zygosity correctly in more
than 96% of cases.18
Case identification
Diagnostic criteria were limited to codes 135.99 and D86.0–D86.9
of the 8th and 10th editions of the International Classification of
Diseases. Information on sarcoidosis in the Danish cohort was
gathered from the Danish National Patient Registry (DNPR) at
the Danish Board of Health on all twins alive between 1977 and
2004. The DNPR contains details on all hospital admissions in
Denmark including information on all diagnostic coding. Cases in
the Finnish cohort included all twins who had applied for medical
reimbursement associated with a diagnosis of sarcoidosis in the
period from 1976 to 2004 (which included 11 186 twin pairs of
working age and not on disability pension in 1975). The Social
Insurance Institution, Finland, grants the right to full reimburse-
ment based on a medical certificate from an appropriate medical
specialist or hospital unit.
Statistical analysis
The Fisher exact test was used to compare probandwise
concordance rates in different zygosity groups. The probandwise
concordance rate denotes the probability that one twin has the
disease given the co-twin is affected, and is estimated as two times
the number of concordant affected pairs (both twins are affected)
divided by two times the number of concordant affected pairs
plus the number of discordant pairs (one twin is affected).19
Recurrence risk ratios were calculated by dividing the
probandwise concordance rate by the prevalence rate, denoting
the increased risk of disease relative to the general population.
The heritability, which is the proportion of variation in
susceptibility ascribable to genetic differences, was estimated
from the number of unaffected, discordant and concordant
pairs. This was based on a multifactorial threshold liability
model and computed according to the methods described by
Neale and Cardon.20
RESULTS
Of 61 662 twin pairs with known zygosity, a total of 210 twin
pairs were identified with at least one diagnosed proband. The
distribution of subjects is shown in table 1. The Danish and
Finnish cohorts did not differ significantly with regard to the
prevalence in the two groups of twins, nor did the prevalence in
monozygotic and dizygotic twins compared in each cohort.
Pooled analysis of the data showed that the probandwise
concordance rate was higher in monozygotic twin pairs than in
dizygotic twin pairs (0.148 vs 0.012, p = 0.012).
Moreover, a co-twin of an affected identical twin has an 80-
fold increased risk of getting sarcoidosis compared with the
general population, whereas the risk was increased only 7-fold
in a co-twin of an affected dizygotic twin.
We found that an aetiological model including genetic and
non-shared environmental effects fitted the data best with a
heritability estimate of 0.66 (95% confidence interval (CI) 0.45
to 0.80). The proportion of variance explained by non-shared
environmental factors was 0.34 (95% CI 0.20 to 0.55).
DISCUSSION
Sarcoidosis has been studied in affected families to reveal any
possible genetic influence on susceptibility. Since families share not
only genes but also environment, aggregation of cases may be due
either to inherited factors or environmental exposures. The
increased relative risk of 5.8 in siblings found in the ACCESS
study9 concurs well with our equivalent finding in dizygotic twins.
However, no studies have partitioned observed familial clustering
into genetic and environmental components of variance.
The significantly higher concordance rate in monozygotic
twins in this study shows that genetic factors appear to play a
substantial role in the susceptibility to sarcoidosis. The
heritability reflects the difference between monozygotic and
dizygotic twin pairs, which tells us that genetic factors account
for two-thirds of the variation in the susceptibility to the
disease whereas environmental factors account for one-third.
Since monozygotic twins are mostly discordant for the
disease, we need to emphasise the importance of additional
environmental risk factors. The heritability estimate does not
reflect the overall risk of getting the disease, merely the variance
between the twins. The genetic influence on the overall risk of
developing sarcoidosis is reflected in the 7-fold versus 80-fold
increased risk in dizygotic and monozygotic twins, respectively.
Aggregation of disease in twins has been described in the
medical literature previously,21 but not with the requisite
statistical power to identify any difference or heritability. It
now seems evident that a considerable component of the disease
accumulation is due to genetic influences on susceptibility.
In spite of the large sample size, we were still left with
relatively few cases to analyse owing to the rarity of the disease.
By pooling the two cohorts we benefited from a larger number
of cases, particularly concordant twin pairs, which also seemed
logical since the prevalence was similar in the two cohorts. The
Finnish data built on reimbursement inclusion criteria which do
not include patients with no need for treatment. An imbalance
of more severe cases is therefore to be expected. There was no
available information on the phenotypic distribution of the
Table 1 Occurrence and resemblance between twins for sarcoidosis in 61 662 Danish and Finnish twin pairs
Zygosity Pairs (n) Prevalence, n (%)
Discordant
pairs (n)
Concordant
pairs (n) CPr
Denmark
MZ 11085 41 (0.185) 37 2 0.098
DZ 39391 129 (0.164) 127 1 0.016
Finland
MZ 3519 13 (0.185) 9 2 0.038
DZ 7667 32 (0.209) 32 0 0
All MZ 14604 54 (0.185) 46 4 0.148
All DZ 47058 161 (0.171) 159 1 0.012
Total 61662 215 (0.174) 205 5 0.030
CPr, probandwise concordance rate.
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cases, so it was not possible to distinguish between genetic
influences on the overall susceptibility and genetic influence on
varying phenotypes as has been suggested by others.10 11
Our results support the notion of sarcoidosis as a complex
disease triggered by a combination of environmental and genetic
risk factors. To get further insight into the interactions causing
the disease, specific genetic, environmental and infectious risk
factors need to be investigated.
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Mechanism of secondary bacterial infection following viral
pulmonary infection (the viral-bacterial synergy)
This paper examines the mechanism causing secondary bacterial infection which often occurs
after pulmonary viral infection. C57BL/6 mice were infected intranasally with influenza virus
strain A/PR8/34(H1N1). By day 12 there was immune-mediated viral clearance; however, the
mice showed a high susceptibility to pneumococcal infection during this recovery stage.
Normal initial bacterial clearance requires innate immunity with bacterial phagocytosis by
resident alveolar macrophages. The phagocytic activity of CD11c+ alveolar macrophages in
bronchoalveolar lavage fluid was lower in virus-infected mice than in virus-naı¨ve mice. To
determine the influence of interferon c (IFNc), the naı¨ve mice were inoculated with exogenous
IFNc which inhibited alveolar macrophage-mediated phagocytosis of pneumococci both in vitro
and in vivo. There was also suppressed surface expression of the class A scavenger receptor
MARCO which is responsible for phagocytosis of pneumococci by alveolar macrophages.
Thirdly, IFNc increased the surface expression of MHC class II antigen. Thus, IFNc inhibits
bacterial phagocytosis and suppresses innate defence against pneumococcal infection. In vivo
treatment with the IFNc-specific antibody XMG1.2 had little effect on the course of viral
infection but prevented increased susceptibility to pneumococcal infection by improved
macrophage expression of inflammatory cytokines and preventing pre-regulation of MHC class
II expression.
This study focuses on the early stages of pneumococcal infection and the crucial role of
alveolar macrophages, the mechanisms of the synergy between influenza virus and Streptococcus
pneumoniae and the inhibitory action of IFNc. There might also be a future therapeutic approach
of IFNc neutralising antibodies for preventing secondary bacterial infections.
c Sun K, Metzger DW. Inhibition of pulmonary antibacterial defense by interferon- c during recovery from influenza infection. Nat Med
2008;14:558–64
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